Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced an evolution and expansion of its Standing in the Gaap program to advance more equitable multiple myeloma care. The program will launch one of the largest U.S. multiple myeloma surveys, engaging >1,000 patients, caregivers and providers.
The survey, developed with leading advocacy groups, builds on a decade of activity since 2016, including >50 educational programs, ~5,000 attendees and a digital community of nearly 60,000, to translate lived experience into community-informed action.
Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 SCOUT-HCM results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy on March 29, 2026. The trial met its primary endpoint with an LS mean Valsalva LVOT gradient reduction of −48.0 mm Hg at Week 28 (P < 0.0001).
Camzyos showed improvements in resting and post-exercise gradients, maximal LV wall thickness, diastolic function (E/e'), and NYHA class versus placebo; safety was similar to adults with no LVEF <50% observed during 28 weeks.
Bristol Myers Squibb (NYSE: BMY) reported Phase 4 data showing symptom stability when switching adults with schizophrenia from oral atypical antipsychotics to Cobenfy (xanomeline and trospium chloride) over 8 weeks.
Key findings: ~86% completed treatment, no discontinuations for lack of efficacy, mean PANSS changes −4.2 (4-week taper) and −3.1 (2-week taper), 49% experienced ≥1 TEAE with no serious TEAEs, and tolerability consistent with prior EMERGENT trials.
Viz.ai will present three abstracts on Viz HCM, its AI-ECG solution within the Viz Cardio Suite, at ACC.26 (March 28–30, 2026).
Key findings include 11 new real-world HCM diagnoses, 13% progression from AI-positive/phenotype-negative over 2.74 years, and that Viz HCM is the first FDA-cleared AI algorithm for HCM detection from a standard 12-lead ECG. The tool was developed under a multi-year agreement with Bristol Myers Squibb (NYSE: BMY).
insitro expanded its ALS collaboration with Bristol Myers Squibb (NYSE: BMY) by adding two targets, ALS-2 and ALS-3, joining ALS-1 (nominated Dec 2024). insitro will advance an oligonucleotide for ALS-1 while BMY progresses a small molecule; insitro received a $10 million milestone.
Using its Virtual Human™ platform, insitro identified targets linked to TDP-43 mislocalization (~97% of ALS) and showed in iPSC-derived motor neurons rescue of neurite growth and reduction of cryptic exons.
Bristol Myers Squibb (NYSE: BMY) will present new clinical and real-world data for Camzyos (mavacamten) at ACC.26 (March 28–30, 2026). Key findings include positive Phase 3 SCOUT-HCM results in adolescents, multiple real-world studies confirming sustained effectiveness and safety, and up to five years of follow-up data.
Camzyos is approved in more than 60 countries, has been prescribed by over 4,500 HCPs to more than 22,000 U.S. patients, and remains available only through a REMS program because of LVEF/heart-failure risks.
Bristol Myers Squibb (NYSE: BMY) announced U.S. and EU approvals expanding Opdivo (nivolumab) indications for classical Hodgkin lymphoma (cHL) on March 20, 2026. In the U.S., Opdivo+AVD is approved for untreated Stage III/IV cHL in patients ≥12 years. In the EU, Opdivo+brentuximab vedotin is approved for relapsed/refractory cHL in patients 5–30 years after one prior therapy. The U.S. decision was supported by Phase 3 SWOG 1826 showing a 58% reduction in risk of progression or death (HR 0.42). Safety signals include 39% serious adverse reactions and 0.6% fatal reactions in SWOG 1826.
Bristol Myers Squibb (NYSE: BMY) will report first-quarter 2026 results on April 30, 2026. Company executives will discuss results on a conference call beginning at 8:00 a.m. ET and a live audio webcast will be available at investor.bms.com.
Materials will be posted on the Investor Relations site before the call, and a replay will be available approximately three hours after the call concludes.
Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma. MeziKd showed a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone.
Safety was consistent with the known profile; patients will continue to be followed for overall survival and long-term safety. Data will be presented at a future medical meeting and shared with health authorities.
Bristol Myers Squibb (NYSE:BMY) announced FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis on March 7, 2026. Approval was supported by pivotal POETYK PsA-1 and PsA-2 trials where Sotyktu 6 mg once daily achieved ACR20 rates of 54% vs placebo 34% (PsA-1) and 54% vs placebo 39% (PsA-2) at Week 16. Common adverse reactions include upper respiratory infections, increased CPK, herpes simplex, mouth ulcers, folliculitis, and acne. Warnings include infections, malignancy including lymphomas, rhabdomyolysis, laboratory abnormalities, and potential risks related to JAK inhibition.